Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

LinkedIn adds a pharma 'influencer'

Pfizer CEO Ian Read joins the likes of Bill Gates and Richard Branson in writing for the social network
LinkedIn Pfizer Ian Read

LinkedIn this week added the first pharma voice to its Influencer articles with a post by Pfizer CEO Ian Read.  

The articles have been contributed from business leaders such as Bill Gates and Richard Branson since October 2012 as part of moves towards publishing that have also seen it launch the LinkedIn Today news service.  

Read's 'You gain respect in drops, but can lose it in gallons' takes aim at the importance of a pharma company's reputation and just one day after publication had amassed more than 8,500 views.  

In terms of engagement the article is doing well too, having so far attracted more than 1,200 shares and 66 comments on LinkedIn, not to mention 45 tweets and 112 Facebook 'likes'.  

LinkedIn influencers

The Pfizer CEO's debut as an Influencer, one of more than 50 names added, including the CEOs of Nissan and Morgan Stanley, comes as LinkedIn starts opening up its publishing platform to its rank and file members.  

Members will be able to share long-form posts to their LinkedIn profile and, in a Facebook-like move, they can be followed by LinkedIn members with which they are not connected.

21st February 2014

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...